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Anti-apoptotic B-cell lymphoma 2 (Bcl-2) family members target several intracellular Ca21-transport
systems. Bcl-2, via its N-terminal Bcl-2 homology (BH) 4 domain, inhibits both inositol 1,4,5-trisphosphate
receptors (IP3Rs) and ryanodine receptors (RyRs), while Bcl-XL, likely independently of its BH4 domain,
sensitizes IP3Rs. It remains elusive whether Bcl-XL can also target and modulate RyRs. Here, Bcl-XL
co-immunoprecipitatedwith RyR3 expressed inHEK293 cells.Mammalian protein-protein interaction trap
(MAPPIT) and surface plasmon resonance (SPR) showed that Bcl-XL bound to the central domain of RyR3
via its BH4 domain, although to a lesser extent compared to the BH4 domain of Bcl-2. Consistent with the
ability of the BH4 domain of Bcl-XL to bind to RyRs, loading the BH4-Bcl-XL peptide into
RyR3-overexpressing HEK293 cells or in rat hippocampal neurons suppressed RyR-mediated Ca21 release.
In silico superposition of the 3D-structures of Bcl-2 and Bcl-XL indicated that Lys87 of the BH3 domain of
Bcl-XL could be important for interacting with RyRs. In contrast to Bcl-XL, the Bcl-XLK87D mutant displayed
lower binding affinity for RyR3 and a reduced inhibition of RyR-mediated Ca21 release. These data suggest
that Bcl-XL binds to RyR channels via its BH4 domain, but also its BH3 domain, more specific Lys87,
contributes to the interaction.
T he B-cell lymphoma 2 (Bcl-2) protein family has long been studied with respect to its prominent role in theregulation of apoptosis1,2. Beyond this, it is becoming increasingly clear that both the pro- and anti-apoptoticBcl-2 family proteins are crucial regulators of intracellular Ca21 signaling. In this way, Bcl-2 proteins affect
various targets related to intracellular Ca21 homeostasis3–5. More specific, this protein family was found to
regulate the mitochondrial voltage-dependent anion channels6–8, plasma-membrane Ca21-ATPases9, sarco/
endoplasmic-reticulum Ca21-ATPases (SERCA)10, Bax inhibitor 111,12, inositol 1,4,5-trisphosphate (IP3) recep-
tors (IP3R)13–15 and ryanodine receptors (RyRs)16.
Anti-apoptotic Bcl-2 proteins are characterized by the presence of four Bcl-2 homology (BH) domains import-
ant for their biological function17. Although their structural organization is very similar, Bcl-2 and Bcl-XLmay act
in very different ways on their targets. As such, the BH4 domain of Bcl-2 is critical for binding to a site in the
regulatory domain of the IP3R (a.a. 1389–1408 for mouse IP3R1) thereby inhibiting IP3-induced Ca21 release14,18.
In contrast, the BH4 domain of Bcl-XL fails to bind to this IP3R domain and to inhibit IP3Rs19. Moreover, we
showed that this difference between the BH4 domains of Bcl-2 and Bcl-XL can largely be attributed to a single
amino acid change (Lys17 in BH4-Bcl-2 corresponding to Asp11 in BH4-Bcl-XL) in the center of their respective
BH4 domains. Indeed, the mutated BH4K17D domain of Bcl-2 and mutated full-length Bcl-2K17D are greatly
impaired in targeting and regulating the IP3R.
We recently showed that, similar to its interaction with the IP3R, Bcl-2 via its BH4 domain targets a RyR region
(a.a. 2263–2688 for mink RyR3) containing a highly conserved regulatory site (a.a. 2309–2330 for mink RyR3),
which shows striking resemblance to the known Bcl-2 binding site on the IP3R16. The interaction of Bcl-2 and the
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RyR via its BH4 domain results in an inhibition of RyR-mediated
Ca21 release. The Bcl-2K17D mutant does not show a dramatic loss of
binding to the RyR and is as potent as wild-type Bcl-2 in inhibiting
RyR-mediated Ca21 release. These results may indicate that in con-
trast to the IP3R, which is differentially targeted by Bcl-2 and Bcl-XL,
RyRs might have a common interaction site for both proteins and do
not distinguish between these two proteins for their regulation.
In this paper, we show that similarly to Bcl-2, Bcl-XL binds to the
RyR via a site located in its central, modulatory domain, thereby
inhibiting RyR-mediated Ca21 release. Although the BH4 domain
of Bcl-XL was sufficient for inhibiting RyRs, we found that in full-
length Bcl-XL not only the BH4 domain but also the BH3 domain
contributed to Bcl-XL/RyR-complex formation. In particular, we
identified Lys87, located in the BH3 domain of Bcl-XL, as an import-
ant contributor of Bcl-XL binding to the RyR.
Results
Bcl-XL binds to RyR3. Bcl-2K17D is a Bcl-2 mutant based on a critical
difference between the BH4 domains of Bcl-2 and Bcl-XL and is
impaired in binding to and regulating IP3Rs19. However, this
mutant still binds to and regulates RyRs with similar efficiencies as
wild-type Bcl-216, suggesting that Bcl-XL may also bind to and regulate
RyRs. Hence, we performed co-immunoprecipitation studies using
lysates from HEK293 cells stably overexpressing RyR3 (HEK RyR3).
In these cells, transiently overexpressed 3XFLAG-tagged Bcl-XL co-
immunoprecipitated with RyR3 indicating the formation of RyR3/Bcl-
XL complexes (Fig. 1A and Supplementary Fig. 1A for uncropped
Western-blot images).
In our previous workwe reported that the interaction between Bcl-
2 and the RyR occurred via the BH4 domain of Bcl-2 and a central
regulatory domain of the RyR (a.a. 22632263–2688 formink 2688 for
mink RyR3)16. To examine whether a direct interaction between
RyRs and the BH4 domain of Bcl-XL exists and whether this inter-
action occurs via the same or similar domains, surface plasmon
resonance (SPR) experiments were performed (Fig. 1B). A concen-
tration-dependent binding between biotin-BH4-Bcl-XL immobilized
to streptavidin coated SPR chips, and the purifiedGST-RyR3 domain
(mink RyR3, a.a. 2263-2688) could be detected. In contrast, but
consistent with our previous observations, purified GST-tagged
IP3R1 domain 3 (mouse IP3R1, a.a. 9232263–2688 for mink 1581),
which is known to bind to the BH4 domain of Bcl-2, failed to bind to
biotin-BH4-Bcl-XL19. While biotin-BH4-Bcl-XL was able to bind to
the GST-RyR3 domain, it seemed to be less effective than biotin-
BH4-Bcl-216. To confirm the proper loading of the biotin-BH4-
Bcl-XL peptide to the sensor chip, we monitored the binding of an
antibody directed against the BH4 domain of Bcl-XL, which caused a
prominent increase in resonance unit (RU) values (Supplementary
Fig. 2). Collectively, these results indicate that the interaction of Bcl-
XL with the RyR3 is direct and that Bcl-XL via its BH4 domain targets
the same domain as Bcl-2 on the RyR. However, the BH4 domain of
Bcl-XL seems to have a lower affinity for the GST-RyR3 domain
compared to the BH4 domain of Bcl-2. This could indicate that
biotinylation of the BH4 domain of Bcl-XL influences its binding
capabilities more than is the case for the BH4 domain of Bcl-2.
Alternatively, other domains besides Bcl-XL’s BH4 domain may be
involved in the interaction of full-length Bcl-XL with the RyR.
Therefore, we wanted to identify if other domains besides the BH4
domain of Bcl-XL are important for interacting with the RyR.
Superposition of the 3D-structures of Bcl-2 and Bcl-XL reveals a
spatial resemblance of Lys17 in the BH4 domain of Bcl-2 with
Lys87 in the BH3 domain of Bcl-XL. To identify the contribution
and involvement of other Bcl-XL domains for targeting RyR
channels, an in silico superposition of the Bcl-2 (PDB-entry
4AQ320) and Bcl-XL (PDB-entry 1R2D21) structures was performed
with the aid of PyMOL (The PyMOL Molecular Graphics System,
Version 1.5.0.4 Schro¨dinger, LLC.). This superposition allowed the
comparison of corresponding residues in the 3D-structures of Bcl-2
and Bcl-XL (Fig. 2). This analysis revealed that the positively charged
e-amino terminus of the side chain of Lys87 in Bcl-XL, located in the
Figure 1 | Bcl-XL binds to a central regulatory region of RyR3. (A)Co-immunoprecipitation experiments were performed utilizing cell lysates fromHEK
RyR3 cells transiently overexpressing 3XFLAG-Bcl-XL. RyR3 was immunoprecipitated from these lysates utilizing a pan-RyR antibody. An anti-FLAG-
HRP conjugated antibody was used for detecting co-immunoprecipitated 3XFLAG-Bcl-XL. Immunoblot showing the immunoprecipitated RyR3 (top)
and co-immunoprecipitated 3XFLAG-tagged Bcl-XL (bottom). Immunoprecipitations using non-specific IgG antibodies were applied as negative
controls. All experiments were performed at least three times utilizing each time independently transfected cells and freshly prepared HEK RyR3 lysates.
All samples were run using the same experimental conditions on the same gel/blot. The uncropped image is shown in Supplementary Fig. 1A. (B)
Sensorgrams of the surface plasmon resonance experiments expressed in RU as a function of time. The biotin-BH4-Bcl-XL peptide and the scrambled
peptide were immobilized on different channels of a streptavidin-coated sensor chip. The channels on the chip were exposed to the indicated
concentrations of purified GST-fusion proteins (GST-IP3R1 domain 3 and GST-RyR3 domain). Binding of the GST-tagged proteins to the scrambled
peptides was subtracted from each sensorgram. GST-IP3R1 domain 3 bound stronger to the scrambled peptide than to the biotin-BH4-Bcl-XL resulting in
apparent negative values after this correction. The black arrow indicates the start of the association phase (addition of the GST-tagged proteins) and the
grey arrow indicates the start of the dissociation phase (running buffer alone). Each sensorgram depicts the average of three experiments (full line)6 S.D.
(dashed lines).
www.nature.com/scientificreports
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BH3 domain, is in the same spatial constraints as the positively
charged e-amino terminus of the side chain of Lys17 located in the
BH4 domain of Bcl-2. Furthermore, Lys87 did not seem to be part of
the hydrophobic cleft of Bcl-XL, as it was directed towards the space
facing the BH4 domain.
The Bcl-XLK87Dmutant is impaired in RyR3 binding.The relevance
of Lys87 in Bcl-XL for RyR binding was addressed via mammalian
protein-protein interaction trap (MAPPIT)22, an in cellulo protein-
protein interaction assay. MAPPIT is based on the functional
complementation of cytokine receptor signaling. To study the
possible existence of RyR/Bcl-XL complexes, the RyR3 domain was
cloned downstream of a chimeric cytokine receptor (RyR3 bait),
consisting of the extracellular domain of the erythropoietin (Epo)
receptor fused to the transmembrane and cytosolic part of the leptin
receptor. In the latter, three tyrosines were mutated to phenylalanine
to down regulate receptor signaling. Bcl-XL or the Bcl-XLK87D mutant
were cloned downstream of a part of the glycoprotein 130 receptor
(Bcl-XL or Bcl-XLK87D prey). If the Bcl-XL and Bcl-XLK87D prey
constructs interact with the RyR3 bait construct, functional
complementation of the chimeric cytokine receptor occurs, leading
to ligand-dependent downstream STAT signaling. The latter is
monitored via a luciferase reporter assay driven by a STAT-
sensitive promoter. We also used the SV40 large antigen T
(irrelevant prey) as a prey to monitor the signal representing the
non-specific binding to RyR3. As a negative control, binding of the
chimeric cytokine receptor without the RyR3 fragment (no bait) to
the two Bcl-XL preys was also assessed. These MAPPIT results
confirmed the data obtained via SPR and co-immunoprecipitation
experiments, showing that Bcl-XL could interact with the RyR3
domain in a cellular context (Fig. 3A, top). Moreover, the Bcl-
XLK87D mutant was severely impaired in interacting with the RyR3
domain without affecting its expression (Fig. 3A, bottom panel and
Supplementary Fig. 1B for uncropped Western-blot images). No
binding was detected when the RyR3 domain was not present in
the bait vector (Fig. 3A, top panel), indicating that the interaction
was specific.
The impact of mutating Lys87 into Asp was also examined in the
context of the full-length RyR3 protein using co-immunoprecipita-
tion experiments. Consistent with the MAPPIT data, 3XFLAG-
tagged Bcl-XLK87D displayed a reduced affinity for full-length RyR3
channels (Fig. 3B and Supplementary Fig. 1C for uncropped
Western-blot images).
Taken together, these data indicate that Bcl-XL, similarly to Bcl-2,
binds via its BH4 domain to the same regulatory domain on RyR3.
However, whereas for Bcl-2 the BH4 domain appears to be the main
determinant for complex formation with RyR channels, it seems that
for Bcl-XL both the BH4 domain and the BH3 domain, likely via
Lys87, contribute to the interaction with RyR channels.
Bcl-XL, but not Bcl-XLK87D, inhibits RyR3-mediated Ca21 release.
Driven by the fact that Bcl-XL can bind to RyR3, we examined
whether Bcl-XL could modulate RyR-mediated Ca21 release
(Fig. 4). Single-cell cytosolic [Ca21] measurements in HEK RyR3
cells loaded with Fura-2-AM were performed (Fig. 4A). An empty
vector (pCMV24) control, 3XFLAG-tagged Bcl-XL or the 3XFLAG-
tagged Bcl-XLK87D mutant were transiently transfected into the HEK
RyR3 cells. An mCherry coding plasmid was co-transfected (at a 1:3
ratio) to identify transfected cells. After chelating extracellular Ca21
with BAPTA (3 mM), caffeine (1.5 mM) was applied to induce RyR-
mediated Ca21 release. Overexpression of 3XFLAG-tagged Bcl-XL
inhibited caffeine-induced Ca21 release compared to the empty
vector control. The Bcl-XLK87D mutant failed to inhibit caffeine-
induced Ca21 release (Fig. 4B), correlating with its poor RyR3-
binding properties. To exclude that the observed reduction in
caffeine-induced Ca21 release upon Bcl-XL overexpression would
have been due to an indirect effect via lowering of the Ca21-filling
state of the endoplasmic reticulum (ER), we determined the amount
of thapsigargin (1 mM)-releasable Ca21. This irreversible SERCA
inhibitor causes a depletion of the ER Ca21 stores and provides a
good measure for the ER Ca21-store content. The ER Ca21-store
content was not affected by overexpression of 3XFLAG-tagged Bcl-
XL (Fig. 4C). This supports the view that Bcl-XL, similarly to Bcl-2,
suppresses RyR-mediated Ca21 release.
The BH4 domain of Bcl-XL by itself seems sufficient to inhibit
RyR-mediated Ca21 release. In order to assess whether the BH4
domain of Bcl-XL is sufficient for inhibiting RyR-mediated Ca21
release, Fluo-3-AM loaded HEK RyR3 cells were loaded acutely
with the BH4 domain of Bcl-XL, a control peptide or the vehicle
via electroporation (Fig. 5A). The BH4 domain of Bcl-XL, but not a
control peptide, suppressed caffeine (1 mM)-induced Ca21 release.
The BH4 domain of Bcl-XL inhibited caffeine-induced Ca21 release
in a concentration-dependent manner (Fig. 5B). This indicates that
the BH4 domain of Bcl-XL was sufficient for inhibiting RyR-
mediated Ca21 release.
We also assessed whether the BH4 domain of Bcl-XL could inhibit
endogenous RyR channels by using 14- to 18-day-old rat hippocam-
pal cultures known to express different RyR isoforms23. The experi-
mental set-up was identical to the one previously used for
characterization of the effect of the BH4 domain of Bcl-2 on native
RyRs16. Cytosolic [Ca21] wasmonitored in GCaMP3-expressing hip-
pocampal neurons. The BH4 domain of Bcl-XL, a control peptide or
the vehicle were introduced into the neurons via a patch pipette.
After loading the neuron for five minutes with the peptides or
Figure 2 | Spatial resemblance of Lys17 in the BH4 domain of Bcl-2 and Lys87 in the BH3 domain of Bcl-XL. Image showing the 3D-structures for Bcl-2
(left), Bcl-XL (middle) and their in silico superposition (right). Lys17 in the BH4 domain of Bcl-2 and Lys87 in the BH3 domain of Bcl-XL
are indicated with arrows. The a.a. in green represent Lys17 and His94 in the BH4 and BH3 domain of Bcl-2 respectively. The a.a. in orange represent
Asp14 and Lys87 in the BH4 and BH3 domains of Bcl-XL respectively. The images were obtained by using PyMOL.
www.nature.com/scientificreports
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vehicle, cytosolic [Ca21] measurements were started. RyR-mediated
Ca21 release was triggered via a local puff of caffeine (10 mM) deliv-
ered via a second patch pipette positioned next to the neuron. A time
lapse (Fig. 5C) and a [Ca21] trace (Fig. 5D) of a typical experiment are
shown for each condition. Loading of the neurons with the BH4
domain of Bcl-XL (20 mM) caused a significant reduction of the
caffeine-induced Ca21 release compared to the control peptide
(Fig. 5 D, E). These results indicate that the BH4 domain of Bcl-XL
can regulate endogenously expressed RyR channels.
Bcl-XL and its BH4 domain directly inhibit RyRs at the level of the
ER.Bcl-XL and its isolated BH4 domain as a synthetic peptide inhibit
the caffeine-induced [Ca21] rise in the cytosol. Bcl-XL has also been
implicated in the control of mitochondrial Ca21 transport at the level
of VDAC1. Bcl-XL was shown to inhibit Ca21 uptake into the
mitochondria6,24. However, it was also reported that Bcl-XL could
stimulate mitochondrial Ca21 uptake25. The latter effect could
result in a decrease in caffeine-induced [Ca21] rise in the cytosol.
Therefore, we set out to document whether the decrease in caffeine-
induced Ca21 release in the cytosol by Bcl-XL is due to a decreased
Ca21 release from the ER or to an increased Ca21 accumulation into
the mitochondria. Direct ER-Ca21 measurements were performed in
HEK RyR3 cells utilizing a recently described green fluorescent
CEPIA1 protein, that is targeted to the lumen of the ER (G-
CEPIA1er)26. HEK RyR3 cells were transiently transfected with the
empty vector (pCMV24) as control or with 3XFLAG-tagged Bcl-XL
in combination with the G-CEPIA1er-encoding vector (at a 351
ratio). G-CEPIA1er-positive cells were selected and measurements
were performed as in Fig. 4A. A typical average trace of one
experiment and the quantification of all performed experiments
are shown in Fig. 6A and B, respectively. These results indicate
that overexpression of 3XFLAG-Bcl-XL suppressed the caffeine-
induced Ca21 release from the ER, supporting a model in which
the inhibitory effect of Bcl-XL on RyR-mediated [Ca21] rise in the
cytosol occurs at least in part due to inhibition of the Ca21 release
from the ER. Finally, we set out to directly measure the effect of the
BH4 domain of Bcl-XL on caffeine-induced mitochondrial Ca21
entry. Rhod-FF-loaded HEK RyR3 cells were electroporated with
either the vehicle (DMSO) or the BH4 domain of Bcl-XL (10 and
20 mM) and then stimulated with caffeine. Caffeine stimulation
resulted in an increase in mitochondrial [Ca21] (Fig. 6C).
Compared to the vehicle control however, the BH4 domain of Bcl-
XL potently inhibited the mitochondrial Ca21 entry (Fig. 6 C, D).
Furthermore, the effectiveness of BH4-Bcl-XL to inhibit caffeine-
induced [Ca21] rise in the mitochondria seemed higher than for
inhibiting the caffeine-induced [Ca21] rise in the cytosol, because
10 mM BH4-Bcl-XL inhibited caffeine-induced Ca21 release in the
cytosol by about 50% but inhibited caffeine-induced Ca21 uptake in
the mitochondria by about 90%. Taken together these data suggest
that BH4-Bcl-XL likely inhibits, rather than stimulates,
mitochondrial Ca21 accumulation. This is consistent with our
recent findings showing that BH4-Bcl-XL directly interacts with
VDAC1 and suppressed VDAC1-mediated Ca21 transfer into the
mitochondria27. These experiments indicate that Bcl-XL can
directly inhibit the caffeine-induced Ca21 release at the level of the
ER and potently inhibit mitochondrial Ca21 uptake under these
Figure 3 | The Bcl-XLK87Dmutant is impaired in RyR3 binding. (A) Top: Representative example of aMAPPIT experiment. The binding is shown as fold
induction value, calculated by dividing the average luciferase value of erythropoietin-stimulated cells by the average of non-stimulated cells. Binding of
Bcl-XL (Bcl-XL prey), the Bcl-XL
K87D mutant (Bcl-XL
K87D prey) or irrelevant prey control (SV40 large T antigen) to the RyR3 domain (RyR3 bait) and as
negative control the bait vector without RyR3 (No bait) are shown. Fold induction values at least 4 times higher than the irrelevant prey control are
considered as bona fide protein-protein interactions. Values represent the average of three repeats within the same experiment 6 S.D. All experiments
were independently performed at least three times. Bottom: OdysseyWestern blot analyses staining for the FLAG tag of the prey vector containing Bcl-XL
or the Bcl-XL
K87D mutant fusion proteins (green) or for actin (red) as a loading control. All samples were run using the same experimental conditions on
the same gel/blot. The uncropped image is shown in Supplementary Fig. 1B. (B) Co-immunoprecipitations were performed inHEKRyR3 cells transiently
overexpressing 3XFLAG-Bcl-XL or 3XFLAG-Bcl-XL
K87D similarly as in Fig. 1A. Non-specific IgG antibodies were applied as negative controls. These
experiments were performed at least three times utilizing each time independently transfected and freshly prepared HEK RyR3 cell lysates. All samples
were run using the same experimental conditions and were derived from the same gel/blot, i.e. 3-8% tris-acetate gels for RyRs and 4-12% bis-tris gels for
3xFLAG-Bcl-XL. The double lines indicate that an additional empty lane separating the immunoprecipitated samples and the input samples was removed
for the 3XFLAG-Bcl-XL blot. The uncropped image is shown in Supplementary Fig. 1C.
www.nature.com/scientificreports
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experimental settings. We therefore conclude that the observed
decrease in caffeine-induced Ca21 release in the cytosol (Fig. 4 and
5) is mainly due to a direct inhibition of RyR3.
Discussion
The main conclusion of this paper is that Bcl-XL binds to and reg-
ulates RyR3 channels. Similarly to Bcl-2, Bcl-XL targets the central
modulatory domain of the RyR protein, thereby suppressing RyR-
mediated Ca21 release. Moreover, the BH4 domain of Bcl-XL was
sufficient to inhibit both over- and endogenously expressed RyR
channels in HEK293 cells or primary rat hippocampal neurons
respectively. Consistent with this, the BH4 domain of Bcl-XL could
bind to the purified RyR3 domain. However, the RyR3-binding effi-
ciency of the BH4 domain of Bcl-XL seemed much lower than that of
the BH4 domain of Bcl-2. Via an in silico superposition of the Bcl-2
and Bcl-XL crystal structures, a spatial overlap was observed between
Lys17 in the BH4 domain of Bcl-2 and Lys87 in the BH3 domain of
Bcl-XL: the positively charged e-amino groups of their side chains
coincide in space. Consistent with themoderate RyR3-binding prop-
erties of the isolated BH4 domain of Bcl-XL, we found that Lys87
from Bcl-XL played a prominent role in binding to and regulating
RyR3.
Figure 4 | Bcl-XL but not Bcl-XLK87D inhibits RyR-mediated Ca21 release. Single-cell cytosolic [Ca21] measurements were performed in HEK RyR3 cells
utilizing Fura-2-AM. (A) Average calibrated [Ca21] trace of 15 to 20 HEK RyR3 cells transfected (mCherry positive) with an empty vector
as control (pCMV24), 3XFLAG-Bcl-XL or 3XFLAG-Bcl-XL
K87D. Addition of BAPTA and caffeine is indicated by the arrows. (B) Quantitative analysis of
the single-cell cytosolic [Ca21] measurements. Values indicate averages of all peak values 6 S.E.M. These experiments were independently performed at
least four times (.120 cells/condition) (p50.008). (C) Quantitative analysis of the ER Ca21-store content. ER-store content was determined by
performing similar experiments as in A except that 1 mM thapsigargin was used as the stimulus. The values indicate the average area under the curve
(AUC) 6 S.E.M. of at least three independent experiments (.80 cells/condition).
www.nature.com/scientificreports
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The association of Bcl-XL with RyR channels and its functional
implications appear to be very similar as the ones observed for Bcl-2,
since i) RyR3/Bcl-XL binding is direct; ii) the binding of Bcl-XL to
RyR3 occurs, at least in part, via the BH4 domain; iii) Bcl-XL over-
expression inhibits RyR-mediated Ca21 release; and iv) the BH4
domain of Bcl-XL is also sufficient to suppress RyR activity. These
Figure 5 | The BH4 domain of Bcl-XL by itself was sufficient to inhibit RyR-mediated Ca21 release. (A) Representative trace of the performed Fluo-3-
AM single-cell cytosolic [Ca21]measurements inHEKRyR3 cells loaded by electroporation with either the vehicle (DMSO), a control peptide or the BH4
domain of Bcl-XL. The addition of caffeine is indicated by the arrow. Traces were normalized to the baseline fluorescence ((F-F0)/F0). (B) Quantitative
analysis of the single-cell cytosolic [Ca21] measurements with indicated concentrations of the BH4 domain of Bcl-XL. Values indicate caffeine-induced
Ca21 release after electroporation loading with different concentrations of the BH4 domain of Bcl-XL relative to the response after electroporation loading
with the same concentration of the control peptide. Values depict average6 S.E.M. of at least four independent experiments (p-values were 0.0037, 0.001
and 0.0039 for 10 mM, 20 mMand 40 mMof the BH4 domain of Bcl-XL respectively). (C-E) Single-cell [Ca
21] measurements performed in 14- to 18-day-
old hippocampal cultures. GCaMP3, introduced into these neurons via adeno-associated infection, was used as cytosolic Ca21 indicator. Utilizing whole-
cell voltage clamp the membrane potential of the neurons was clamped at260 mV. 20 mMof the BH4 domain of Bcl-XL, a control peptide or the vehicle
(DMSO) was introduced into each measured neuron via the patch pipette. All experiments were performed in the presence of 1 mM tetrodotoxin. A
10 mM caffeine puff was locally administered via a second patch pipette positioned 15-25 mm from the soma of the neuron. (C) Time lapse of a typical
experiment for each of the tested conditions. Caffeine was administered after 60 sec. The scale bar depicts 5 mm. (D) Typical responses to caffeine after
loading the neurons with 20 mM of either the control peptide the BH4 domain of Bcl-XL or the vehicle. Traces were normalized to the baseline
fluorescence ((F-F0)/F0). The arrow indicates when caffeine was administered. (E) Scatter plot showing peak responses of all performed measurements
and themedian (horizontal line). All values were normalized to the caffeine response after vehicle control treatment (p50.0037, N512 andN515 for the
control peptide and BH4-Bcl-XL respectively).
www.nature.com/scientificreports
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findings correlate with the fact that the Bcl-2K17D mutant and BH4-
Bcl-2K17D remain capable of binding to and regulating RyR channels,
although this mutation changes the lysine critical for binding to the
IP3R into the Asp11 residue in the BH4 domain of Bcl-XL16. This lack
of selectivity between Bcl-2 and Bcl-XL may illustrate an important
difference between IP3R- and RyR-mediated Ca21 release. However,
the binding of Bcl-XL versus Bcl-2 to RyRs in native tissues expres-
sing RyRs ought to be further explored. In particular, it will be
important to carefully analyze the Bcl-2- and Bcl-XL-expression
levels in the relevant tissues and to determine whether a preferential
binding of Bcl-2 or Bcl-XL to RyR channels exists in cells expressing
both Bcl-2 and Bcl-XL. Despite these similarities, the molecular
determinants underlying RyR/Bcl-XL-complex formation do not
seem identical to those of Bcl-2, because the BH4 domain of Bcl-
XL by itself displays rather moderate RyR3-binding properties. As a
consequence, additional domains seem to be involved in RyR/Bcl-
XL-complex formation. Here, we identified Lys87, located in the BH3
domain of Bcl-XL, as a critical determinant contributing to binding to
and regulating RyR channels. Despite the importance of Lys87, the
BH4 domain of Bcl-XL alone was able to suppress RyR activity.
The BH4 domain of Bcl-XL has been implicated in numerous
studies to display strong anti-apoptotic and protective effects against
a wide variety of insults and triggers, including in the heart28-30,
endothelial cells31,32, blood cells33-35, pancreatic islets36 and neurons37.
Many of the cell types and tissues reported to benefit from the BH4
domain of Bcl-XL for their survival endogenously express RyR chan-
nels (cardiomyocytes, lymphocytes, pancreatic islets and neurons).
Furthermore, in many apoptotic paradigms, reactive oxygen species
Figure 6 | Bcl-XL and its BH4 domain directly inhibit RyR-mediated Ca21 release from the ER. (A) Typical average normalized (F/F0) traces of single-
cell ER [Ca21] measurement performed in HEK RyR3 cells transfected with G-CEPIA1er plasmid. G-CEPIA1er-positive cells transfected with the empty
control vector (pCMV24) or 3XFLAG-Bcl-XL were selected for thesemeasurements. After chelating extracellular Ca
21 with BAPTA, caffeine was added to
stimulate RyR-mediated Ca21 release (arrows). (B) Quantitative analysis of the performed experiments. For each trace the caffeine-induced Ca21 release
was determined by subtracting the fluorescence after caffeine addition (during plateau phase) from the fluorescence just before caffeine addition after
normalization. Values depict average 6 S.E.M. These experiments were independently repeated at least four times (.100 cells/condition) (p50.0018).
(C)Normalized ((F-F0)/F0) representative traces ofmitochondrial [Ca
21]measurements. The vehicle (DMSO) or the BH4 domain of Bcl-XL (10 mMand
20 mM) were introduced into Rhod-FF-loaded HEK RyR3 cells via electroporation loading. Mitochondrial Ca21 was measured after caffeine (arrow)
stimulation. (D) Quantification of the performed experiments. Values show the average caffeine-induced mitochondrial Ca21 entry as area under the
curve (AUC) 6 S.E.M. Experiments were independently performed at least three times (p,0.0001).
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(ROS) are implicated. ROS can impact the redox state and activity of
the RyR channels (reviewed by Ref. 38). Mild increases in ROS mod-
erately increase RyR activity by increasing its sensitivity for Ca21 39.
However, severe ROS production associated with oxidative stress
(e.g. in the context of ischemia/reperfusion injury) can lead to a
continuously opening of the RyR channels, provoking an excessive
Ca21 leak from the ER or sarcoplasmic reticulum40. In the context of
the heart, ROS has been clearly implicated to cause unzipping of the
interdomain interactions critical for RyR2-channel stabilization41,42.
During oxidative stress conditions, the BH4 domain of Bcl-XL may
thus inhibit excessive RyR-mediated Ca21 release from the intracel-
lular Ca21 stores in addition to exerting its protective effects at the
mitochondria, thereby providing additional protection against cell
death.
RyRs have important physiological functions in a variety of excit-
able cells and tissues, including skeletal muscle, cardiac muscle, neu-
rons and pancreatic cells43–46. Furthermore, dysregulation of RyRs,
either by somatic mutations or by altered expression levels, has been
implicated in a variety of pathophysiological conditions, including
malignant hyperthermia and central core disease47,48, cardiac dis-
eases49–51 and neurodegenerative diseases like Alzheimer’s dis-
ease52–54 and Huntington’s disease55. At this point, the existence
and physiological relevance of RyR/Bcl-2- and RyR/Bcl-XL-complex
formation in these tissues and their potential disturbance in RyR-
associated pathophysiologies will require further research.
In conclusion, our data further expand the number of Bcl-2-family
members that are able to form protein complexes with RyR channels,
thereby underpinning their critical role in regulating intracellular
Ca21 dynamics at the level of intracellular Ca21-release channels.
Methods
Chemicals, antibodies and peptides. Unless otherwise specified, all chemicals were
purchased from Sigma-Aldrich (St. Louis, MO, USA). The following antibodies were
used: mouse monoclonal anti-actin antibody, anti-FLAG M2 antibody and HRP-
conjugated anti-FLAG M2 antibody (Sigma-Aldrich), mouse monoclonal anti-RyR
antibody 34C (Thermo Scientific, Rockford, IL, USA, or Developmental Studies
Hybridoma Bank, University of Iowa, Iowa, USA) and mouse monoclonal anti-Bcl-
XL antibody YTH-2H12 (Trevigen, Gaithersburg, WV, USA). The sequences of the
peptides used in this study were:
Biotin-BH4-Bcl-XL: Biotin-MSQSNRELVVDFLSYKLSQKGYSW (also used
without the biotin tag)
Biotin-scrambled BH4-Bcl-XL: Biotin-WYSKQRSLSGLVMYVLEDKNSQFS
Control peptide: WYEKQRSLHGIMYYVIEDRNTKGYR
These peptides were synthesized by Life Tein (Hillsborough, NJ, USA) with a
purity of at least 85%.
Plasmids, constructs and protein purifications. 3XFLAG-Bcl-XL was obtained as
previously described19. The 3XFLAG-Bcl-XLK87D mutant was obtained by PCR site-
directed mutagenesis utilizing the following primers: forward:
59ATCCCCATGGCAGCAGTAGATCAAGCGCTGAGGGAGGCA39, and reverse:
59TGCCTCCCTCAGCGCTTGATCTACTGCTGCCATGGGGAT39. The pCMV
G-CEPIA1er containing plasmid was a gift from Dr. Masamitsu Iino (Addgene
plasmid # 58215)26. The GST-IP3R1 domain 3 construct and the GST-RyR3 construct
were obtained and purified as described16.
Cell culture, transfections and dissociated hippocampal cultures. All media and
supplements added to the medium used in this paper were purchased from Life
Technologies (Ghent, Belgium). HEK293 cells stably overexpressing RyR3 were
cultured at 37uC in a 5% CO2 incubator in a-Minimum Essential Medium
supplemented with 10% fetal calf serum, 100 IU/mL penicillin, 100 mg/mL
streptomycin, 2 mM glutamax and 800 mg/mL G41856. HEK293 cells were grown in
Dulbecco’s Modified Eagle Medium containing 4500 mg/L glucose, 10% fetal bovine
serum and 50 mg/mL gentamicin57.
24 hours after seeding, the 3XFLAG-Bcl-XL or the 3XFLAG-Bcl-XLK87D mutant
construct were introduced into the HEK RyR3 cells utilizing JETPrime transfection
reagent (Polyplus Transfections, Illkirch, France) according to the manufacturer’s
protocol. 48 hours later the cells were harvested and lysed utilizing a CHAPS-based
lysis buffer (pH 7.5, 50 mM Tris-HCl, 100 mM NaCl, 2 mM EDTA, 50 mM NaF,
1 mM Na3VO4, 1% CHAPS and protease inhibitor tablets (Roche, Basel,
Switzerland)). For single-cell cytosolic [Ca21] measurements the same constructs or
the empty pCMV24 vector were introduced 48 hours after seeding in the HEK RyR3
cells utilizing X-tremeGENE HP DNA transfection reagent (Roche) according to the
manufacturer’s protocol. A pcDNA 3.1(-) mCherry expressing vector was co-trans-
fected at a 153 ratio as a selectionmarker. For direct ER [Ca21] measurements, the G-
CEPIA1er construct was co-transfected (ratio 351) and used as selection marker
instead of the mCherry expressing vector. Dissociated hippocampal cultures were
obtained as described previously58. All animal experimentswere performed according
to approved guidelines.
SPR analysis. SPR analysis was performed using a Biacore T200 (GE Healthcare,
Diegem, Belgium). Immobilization to the streptavidin-coated sensor chip (BR-1005-
31; GEHealthcare) and SPRmeasurements were performed as described previously19.
NaOH (50 mM) with 0.0026% SDS was used as a regeneration buffer.
Immunoblot analysis. Samples were prepared and used as previously described19. For
visualization of RyRs, NuPAGE 3–8% tris-acetate gels were run. Detection was
performed using Pierce ECLWestern Blotting Substrate (Thermo Scientific) when using
the ChemidocTM MP system (Bio-Rad, Nazareth Eke, Belgium) or an X-OMAT 1000
processor (Kodak, Zaventem, Belgium). When using the Odyssey imager (Westburg,
Leusden, The Netherlands) detection was performed using anti-mouse-IRDye800
(green) or anti-rabbit-IRDye700 (red) as secondary antibodies (Thermo Scientific).
Co-immunoprecipitation experiments. Co-immunoprecipitation experiments
were performed utilizing a co-immunoprecipitation kit (Thermo Scientific). RyR
antibody or mouse IgG control antibody (Santa Cruz Biotechnology, Heidelberg,
Germany) was immobilized according to the manufacturer’s protocol. Gelatine was
removed from the IgG control antibody utilizing a Pierce Antibody Clean-up Kit
(Thermo scientific). Precleared HEK RyR3 lysates containing the 3XFLAG-Bcl-XL
constructs (150 mg) were added to the resin to which the antibodies were immobilized
and allowed to incubate overnight at 4uC. The next day, the resin was washed at least
five times utilizing theCHAPS-based lysis buffer. The immune complexes were eluted
by boiling (95uC) in 50 mL 23 LDS (Life Technologies) supplemented with 1/200 b-
mercaptoethanol for 5 min.
MAPPIT. The RyR3 domain was amplified by PCR using the following primers,
forward: 59TAGTTGTCGACGAAGAGAGAAGTCATGGAGGA39, and reverse:
59TAGTTGCGGCCGCCTATTTGGTCCTCTCCACA39, and cloned in the
pSEL12L bait vector59, using the restriction enzymes SalI and NotI. Bcl-XL was
cloned in the pMG1-GW plasmid (prey vector)22 using the Gateway recombination
technology as described by the manufacturer (Life Technologies). Utilizing the same
primers as described before, the Bcl-XLK87D mutation was also introduced in this
construct via site directed mutagenesis. The MAPPIT analyses were done as
previously described22 with minor changes. Briefly, HEK293 cells were seeded in 96-
well plates. Six wells per condition were transfected with the different combinations of
bait, prey and reporter plasmid (rPAP1-luci) using the calcium phosphate method.
The next day, half of the wells were stimulated with 5 ng/mL Epo while the other half
were left untreated. 24 hours later the cells were lysed and after the addition of
substrate the luciferase activity was determined using a luminometer. The fold
induction was obtained by dividing the average value of the stimulated cells by the
average value of the non-stimulated cells.
Electroporation loading. Electroporation loading of HEK RyR3 cells was performed
as previously described16,60.
Single-cell cytosolic Ca21 imaging. Fura-2-AM and Fluo-3-AM [Ca21]
measurements in HEK RyR3 cells and GCaMP3 single-cell [Ca21] measurements in
dissociated hippocampal neurons were performed as previously described16.
Single-cell ER Ca21 imaging. The G-CEPIA1er construct was introduced into HEK
RyR3 cells as described above. A Zeiss Axio Observer Z1 Inverted Microscope
equipped with a 203 air objective and a high-speed digital camera (Axiocam Hsm,
Zeiss, Jena, Germany) were used for these measurements. Changes in fluorescence
were monitored in the GFP channel (480/520 excitation/emission). To chelate
extracellular Ca21, 3 mMBAPTA (Alfa Aesar, Ward Hill, MA, USA) was added. One
minute later 1.5 mM caffeine was added to trigger RyR-mediated Ca21 release. All
traces were normalized (F/F0) where F0 is the starting fluorescence of each trace.
Single-cell mitochondrial Ca21 imaging. HEK RyR3 cells were loaded for 30 min
with 5 mMRhod-FF-AM. Subsequently, cells were subjected to de-esterification over
15 min. During this time the BH4 domain peptides were introduced into the cells
using the in situ electroporation technique60. Fluorescence-intensity changes in
mitochondria were analyzed with custom-developed FluoFrames software. For each
individual trace, the relative change of fluorescence (DF/F) was calculated. DF/F
equals [Ft-F0/F0], with F0 denoting the fluorescence before stimulation with caffeine
and Ft the fluorescence at different time points after caffeine stimulation.
Subsequently, relative mitochondrial [Ca21] changes were quantified as the area
under the curve of the various Ca21 traces.
Statistical analysis. Two-tailed student’s t-tests were performed when two conditions
were compared. When comparing three conditions a one-way ANOVA with
Bonferroni’s multiple comparison test was performed. * indicates significantly different
results (p,0.05). Exact p-values are indicated in the figure legends, where available.
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